Would you sign a financial contract today that locks in your 2024 to 2026 cost structure for the next ten years?

That is essentially the bet LEAD asks ACOs to make. CMS has positioned the model as a 10-year voluntary structure with no traditional rebasing, broader participation design, prospective payment options, and specialist integration through CMS-Administered Risk Arrangements (CARA). For the right participants, the opportunity is significant. For the wrong ones, it is a decade of carrying baseline decisions made before the ink was dry.

The real question is not whether LEAD replaces REACH in policy terms. It is whether LEAD replaces REACH in your operating model. Here are the questions I hear most often from population health leaders working through that decision.

1.   How does the CMS LEAD Model 2027 benchmark affect ACO strategy?

This is the biggest concern among population health leaders. CMS says LEAD establishes a ten-year performance period without rebasing and uses a three-year historical baseline with annual updates tied to prospective trends plus observed national and regional spending. CMS also describes a pathway toward longer-term benchmark stability rather than repeated resets.

This is why experienced ACO leaders are not reacting to “no rebasing” enthusiastically. They are evaluating whether their baseline is strong enough to justify locking it in for ten years. 

For a PY 2027 entrant, your fixed base years are calendar years 2024, 2025, and 2026. Those three years follow you through 2036. If your coding and utilization in that window understated complexity, you live with that for a decade. If it overstated complexity, you live with that too. Most leaders we talk to have not actually pressure-tested whether their CY 2024 to CY 2026 spend pattern is the version of their organization they want to lock in.

There is also an asymmetry that has not gotten much attention. ACOs eligible for both the Regional Efficiency Adjustment and the Prior Savings Adjustment receive the higher of the two, capped at 5% of US per capita cost. ACOs transitioning from the Shared Savings Program are capped at 3%. Experienced low-cost MSSP graduates have less headroom in LEAD than the headline math suggests, and that affects how attractive the move is.

2.   If we serve high-needs or dual-eligible populations, will LEAD actually pay us fairly enough to justify the move?

CMS is clearly trying to make LEAD more viable for organizations serving complex populations. The model overview and FAQs emphasize improved benchmarking and risk adjustment for High Needs beneficiaries, lower alignment minimums for ACOs with large High Needs populations, and a two-state planning effort to develop Medicare-Medicaid partnership frameworks for dually eligible beneficiaries in Original Medicare. That is directionally important. It is not the same as guaranteed fit.

Organizations serving high-needs or dual-eligible populations should be asking three harder questions. Will our coding and attribution processes capture complexity well enough at baseline? Is our care model mature enough to turn improved risk treatment into tangible performance? And are we expecting the duals component to do more in the near term than CMS has actually committed to?

LEAD may be more favorable to these populations than prior models, but only if the underlying financial model is disciplined enough to prove it.

There is also a workflow change buried in here that almost no one is talking about. LEAD applies concurrent risk adjustment to High Needs beneficiaries, using diagnoses from the same performance year rather than the prior year. That sounds technical. In practice, it means your coding and documentation cycle has to operate inside the performance year, not after it. ACOs running prospective-model workflows under MSSP will need to rebuild how risk capture actually happens day-to-day. If your current playbook is retrospective coding cleanups, that playbook does not work in LEAD.

3.   Are we actually ready to use prospective payment well?

CMS says LEAD offers Professional and Global risk options along with Primary Care Capitation and, for Global ACOs, Total Care Capitation, plus additional payment mechanisms beyond those core options. These prospective payments are meant to help ACOs invest earlier in preventive and proactive care.

Can you turn population-based cash flow into staffing, access, and care-management discipline? Can finance, clinical operations, and contracting work from the same playbook? Or will prospective payment simply expose weak coordination between them? A surprising number of organizations are comfortable talking about capitation and still unprepared to manage it.

Read CMS’s own Payment Example #1 carefully. The Enhanced PCC line shows about $340K per month in capitated payment. Then read the footnote. CMS labels that line “$0 net new revenue because it is paid monthly but must be re-paid at the end of the year.” In other words, a substantial portion of LEAD’s prospective payment is a cash flow advance, not new money. If your finance team treats the advance as revenue, your reconciliation will surprise you. Which dollars are durable and which dollars are timing? That is the conversation that needs to happen before you sign the participation agreement, not after.

4.   Is CARA a real strategic opportunity for us, or just another layer of execution burden?

CARA is a voluntary initiative for LEAD ACOs in the Global Risk Option that provides the infrastructure to negotiate episode-based risk arrangements with specialists. CMS says CARA is intended to reduce barriers to specialist integration by supplying data, standard provisions, and concurrent reconciliation support.

The ACOs most likely to benefit are the ones that already have concentrated specialty spend, a clear episode strategy, and enough data maturity to track specialist performance in a timely way. The ones most likely to struggle are those treating CARA as a concept they can figure out later.

A few practical realities about CARA that are easy to miss. It is only available to ACOs in the Global Risk Option, so choosing CARA effectively chooses your risk track. Its first performance year is 2028, with first reconciliation in mid-2029, so you are committing to specialist contracting work for an initiative that produces no financial signal for two years after launch. And ACOs in CARA must execute a separate participation agreement amendment (the LPACA) that most legal and contracting teams have not budgeted into their LEAD readiness plan. None of this makes CARA a bad bet. It does mean CARA is a bigger commitment than the marketing suggests.

5.   How much of LEAD’s upside depends on capabilities we do not yet have?

CMS’s application checklist requires explicit decisions on alignment approach, risk option, payment structure, intended High Needs and spending status, interest in CARA and Medicaid partnerships, financial guarantee, care delivery strategy, data and health IT capabilities, governance, compliance, and vendor use.

That list reveals what LEAD participation actually requires. The most useful internal question is not “Do we have a population health platform?” It is “Where is the gap between our LEAD strategy and our day-to-day operating reality?”

For some ACOs, the gap is benchmark modeling. For others, it is specialist data, beneficiary engagement, or governance discipline. In LEAD, those are not side issues. They determine whether the model’s flexibility becomes operating leverage or just another source of exposure.

Two requirements get underestimated. First, every LEAD ACO has to develop and implement a Prevention and Quality Plan starting in PY 2027, with payment tied to development and goal attainment. If you do not already have a defined prevention strategy running in your aligned population, you are building one while absorbing every other Year 1 transition demand. Second, the new electronic clinical quality measures phase in slowly: optional in PY 2027 and 2028, pay-for-reporting in 2029 and 2030, required after that. The phase-in feels gradual until you realize it is a forcing function. If your EHR-to-quality-reporting pipeline is not production-ready by 2029, you are carrying quality withhold risk against capabilities you have not built yet. ACOs tend to assume they have time. They have less than they think.

6.   What does the AI risk adjustment transition mean for our 10-year bet?

CMS has signaled that risk adjustment for the aged and disabled population will eventually move away from CMS-HCC toward an AI-inferred model. The expected timeline is a blended approach starting around 2029, with full transition in PY 2031. CMS has not yet defined how the model will be built, validated, audited, or governed. Transparency, explainability, and stability through the transition are all open questions.

For ACO leaders, this changes the shape of the bet. The first four years of LEAD use risk adjustment infrastructure most organizations already understand. The back half of the model may run on infrastructure that has not been published yet. That is not a reason to avoid LEAD. It is a reason to ask whether your data and analytics roadmap is set up to absorb a methodology change mid-flight without disrupting care management, coding, and benchmark assumptions all at once. No prior CMS model has asked participants to commit to a decade of accountability while signaling that one of the most consequential financial inputs will change halfway through.

7.   What should a leadership pressure-test before deciding LEAD versus MSSP?

Before choosing LEAD, leadership should pressure-test five things:

1. Baseline sensitivity: how much does year-one coding or utilization variation change our long-term economics?
2. Population fit: how much of our attributed population is high-needs, dual-eligible, rural, or otherwise positioned to benefit from LEAD’s design?
3. Payment readiness: can we use prospective payment as an operating tool rather than just a financing mechanism?
4. Specialist strategy: do we have enough concentrated specialty opportunity to make CARA worth the lift?
5. Downside tolerance: are we ready for the financial and governance demands of a model designed to last ten years?

8.   How should we think about political and program risk over a 10-year horizon?

LEAD is authorized under Section 1115A. The RFA explicitly reserves CMS’s right to modify or terminate the model if it is not achieving its aims. That is standard CMMI language, and most leaders skim past it. In a model that asks for ten years of commitment, it is worth a closer look.

Ten years spans at least two presidential administrations and likely several CMMI directors. Priorities shift. REACH itself was rebranded from Direct Contracting under political pressure and was sunset four years into a longer planned arc. ACO models in general have a track record of mid-stream design changes to risk corridors, benchmarks, quality measures, and waivers, often after participants have already made commitments. The AI risk adjustment transition is itself a mid-stream change, and a politically sensitive one.

None of this argues against LEAD. It argues for entering LEAD with a clear view of what kind of commitment you are actually making. A ten-year economic bet with limited exit optionality is a different thing from a ten-year planning horizon. Build your downside scenarios with that in mind.

Final thoughts

LEAD is compelling for the same reason it feels risky. CMS is offering more time and structural flexibility to support long-term accountable care. But more time only helps if the organization is ready to use it well.

That is why the most useful LEAD question is not “What does the model allow?” It is “What kind of ACO does this model reward, and are we built to be one?”

‍